European Journal of Surgical Oncology
Volume 35, Issue 11 , Pages 1158-1163 , November 2009

A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study)

  • Y. Kodera

      Affiliations

    • Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 52 744 2250; fax: +81 52 744 2255.
    • ,
  • S. Ito

      Affiliations

    • Department of Gastroenterological Surgery, Aichi Cancer Center Chuo Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan
    • ,
  • Y. Mochizuki

      Affiliations

    • Department of Gastroenterological Surgery, Aichi Cancer Center Chuo Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan
    • ,
  • K. Kondo

      Affiliations

    • Department of Surgery, Nagoya Medical Center, 4-1-1, Sannomaru, Naka-ku, Nagoya, Aichi 460-0001, Japan
    • ,
  • K. Koshikawa

      Affiliations

    • Department of Surgery, Komaki Municipal Hospital, 1-20, Jobushi, Komaki, Aichi 485-5820, Japan
    • ,
  • N. Suzuki

      Affiliations

    • Department of Surgery, Aichi Koseiren Atsumi Hospital, 1-1, Akaishi, Kobe-cho, Tahara, Aichi 441-3415, Japan
    • ,
  • H. Kojima

      Affiliations

    • Department of Surgery, Aichi Cancer Center Aichi Hospital, 18 Ketsumachi Aza Kuriyado, Okazaki, Aichi 444-0011, Japan
    • ,
  • T. Kojima

      Affiliations

    • Department of Surgery, Aichi Cancer Center Aichi Hospital, 18 Ketsumachi Aza Kuriyado, Okazaki, Aichi 444-0011, Japan
    • ,
  • T. Matsui

      Affiliations

    • Department of Surgery, Aichi Cancer Center Aichi Hospital, 18 Ketsumachi Aza Kuriyado, Okazaki, Aichi 444-0011, Japan
    • ,
  • T. Takase

      Affiliations

    • Department of Surgery, Aichi Koseiren Kainan Hospital, 396 Minami Honda, Maegasu-cho, Yatomi, Aichi 498-8502, Japan
    • ,
  • K. Tsuboi

      Affiliations

    • Department of Surgery, Koritsu Tosei Hospital, 160 Nishi Oiwake-cho, Seto, Aichi 489-8642, Japan
    • ,
  • M. Fujiwara

      Affiliations

    • Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
    • ,
  • A. Nakao

      Affiliations

    • Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
    • ,
  • for Chubu Clinical Oncology Group

,Accepted 5 March 2009.

References 

  1. Ekstrom AM, Hansson LE, Signorello LB, Lindgren A. Decreasing incidence of both major histologic subtypes of gastric carcinoma – a population-based study in Sweden. Br J Cancer. 2000;83:391–396
  2. Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer. 1997;80:2333–2341
  3. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18–29
  4. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236–242
  5. Maehara Y, Hasuda S, Koga T, et al. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2000;78:353–357
  6. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730
  7. Kodera Y, Yamamura Y, Shimizu T, et al. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol. 1999;72:60–64
  8. Japanese Gastric Cancer Association . Japanese classification of gastric carcinoma – 2nd English edition. Gastric Cancer. 1998;1:10–24
  9. Bonenkamp JJ, Songun I, Hermans J, van de Velde CJ. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg. 1996;83:672–674
  10. Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12:347–353
  11. Sarela AI, Miner TJ, Karpeh MS, Coit DG, Jaques DP, Brennan MF. Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg. 2006;243:189–195
  12. Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715–1720
  13. Sugimachi K, Maehara Y, Horikoshi N, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology. 1999;57:202–210
  14. Kinoshita T, Nashimoto A, Yamamura Y, et al. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer. 2004;7:104–109
  15. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, and oral fluoropyrimidine. N Engl J Med. 2007;357:1810–1820
  16. Nakanishi H, Mochizuki Y, Kodera Y, et al. Chemosensitivity of peritoneal micrometastasis as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Cancer Sci. 2003;94:112–118
  17. Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003;21:2282–2287
  18. Kodera Y, Ito S, Mochizuki Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res. 2007;27:2667–2671
  19. Ajani JA, Faust J, Ikeda K, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005;23:6957–6965
  20. Degiuli M, Sasako M, Ponti A, Soldati T, Danese F, Calvo F. Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol. 1998;16:1490–1493
  21. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol. 2006;7:309–315
  22. Fujimura T, Yonemura Y, Nakagawara H, et al. Subtotal peritonectomy with chemohyperthermic peritoneal perfusion for peritonitis carcinomatosa in gastrointestinal cancer. Oncol Rep. 2000;7:809–814
  23. Kodera Y, Ito Y, Ito S, et al. Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology. 2007;54:960–963
  24. Ohashi N, Kodera Y, Nakanishi H, et al. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol. 2005;27:637–644
  25. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–221
  26. Mori T, Fujiwara Y, Sugita Y, et al. Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative chemotherapy in advanced gastric carcinoma. Ann Surg Oncol. 2004;11:14–20

PII: S0748-7983(09)00079-1

doi: 10.1016/j.ejso.2009.03.003

European Journal of Surgical Oncology
Volume 35, Issue 11 , Pages 1158-1163 , November 2009

Article Tools

* Image Usage & Resolution